The Globe and Mail reports in its Wednesday, March 4, edition that Barclays analyst Benjamin Theurer continues to rank Nutrien "equal weight." The Globe's David Leeder writes in the Eye On Equities column that Mr. Theurer gave his share target a $10 boost to $80 (all figures U.S.). Analysts on average target the shares at $73.06. Mr. Theurer says in a note: "The United States/Israel strikes on Iran have potential to bolster nitrogen pricing for at least 1H26, providing further upside for North American producers, given the strain on LNG in the EU. Potash should be fairly stable while phosphate will face higher ammonia input costs. We stay 'overweight' CF and downgrade MOS to EW." The Globe reported on July 16, 2024, Oct. 3, 2024, May 13, 2025, and Feb. 24, 2026, that RBC Capital Markets analyst Andrew Wong was sticking with his "outperform" recommendation for Nutrien. The shares could then be had for $50.91, $49.94 and $58.06.